Phase III Gantenerumab Trial for Prodromal Alzheimer’s Disease Discontinued (Biospace Inc)

Summary

The Scarlet RoAD study (a Phase III trial), researching the anti-amyloid drug Gantenerumab for the possible treatment of prodromal (pre-dementia) Alzheimer’s Disease, has been abandoned following disappointing results.

Gantenerumab-related research (in a different Phase III investigation) is still underway for the possible treatment of Alzheimer’s Disease at a later stage. Roche remains committed to drugs development for dementia generally.

Full Text Link

Reference

Roche (RHHBY) suffers a double blow as breast cancer, Alzheimer’s drug studies fail; pulls plug on ALZ’s drug development. [Online, USA]: Biospace Inc., December 19th 2014.

Advertisements

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights and tagged , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.